GASTROPARK: Multicenter study on the efficacy of dopamine agonists for gastrointestinal symptoms in Parkinson’s disease
Objective: Main: To assess the modification of gastrointestinal symptoms in patients with Parkinson's disease before and after the introduction of dopamine agonists. Secondary: (1) To…Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience
Objective: To explore if catechol-O-methyl-transferase inhibition (COMT-I) can prolong the efficacy of daytime intrajejunal Levodopa infusion (IJLI) in Parkinson’s disease (PD) along with a reduction…Combination Therapy of Ellagic Acid and Mucuna Pruriens Seeds Extract Improves Rotenone Induced Behavioural, Oxidative and Mitochondrial Deficits in Mice Model of Parkinson’s Disease
Objective: The present study was designed in order to explore the possible synergistic effect of two highly naturally occurring bio-active compounds viz. Ellagic acid (EA)…Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson
Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)
Objective: To evaluate whether levodopa induced dyskinesia is preventable in the treatment of patients with Parkinson’s disease. Background: Dyskinesia is one of the major complications…Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A) receptor EMD-281,014 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…The change of heart rate variability after subthalamic nucleus deep brain stimulation in patients with Parkinson’s disease: A Meta⁃analysis
Objective: To evaluate the changes of heart rate variability (HRV) after subthalamic nucleus deep brain stimulation (STN-DBS) in patients with Parkinson’s disease (PD). Background: The…Hemidystonia due to midbrain hemorrhage: An unusal complication of Deep Brain Stimulation
Objective: In this case report, we describe the development of hemidystonia due to hemorrhagic complication after subthalamic deep brain stimulation (STN-DBS) in a patient with…The Characteristics of Patients with Movement Disorders in a Diverse Inner-City Hospital
Objective: To investigate healthcare disparities in provision of care to Parkinson's disease (PD) and PD-plus patients in an ethnically diverse population in an inner-city hospital.…Baseline predictors of clinical and imaging progression in Parkinson’s disease: Results from the PPMI study
Objective: To identify clinical, imaging, and biochemical measures, obtained early in the disease course that predict clinical and dopamine transporter (DAT) imaging progression in PD.…
- « Previous Page
- 1
- …
- 216
- 217
- 218
- 219
- 220
- …
- 388
- Next Page »